Anna‐Katharin Theuser

Adherence of Patients With Breast Carcinoma and Gynecologic Genital Carcinoma in the Use of Integrative Therapy Recommendations

Milena Beierlein, Carolin C. Hack, Anna‐Katharin Theuser, Katharina Au et autres

BackgroundThis study aimed to evaluate differences in adherence to integrative therapy recommendations provided by the Consultation Service for Integrative Medicine (SIM) at the Women's Clinic of the University Hospital Erlangen, Germany, across patient subgroups. The study sought to identify opportunities for further …

de (code pays fourni par la source)

Regelkonform forschen – GCP-konformes Arbeiten im Rahmen klinischer Studien

Anna‐Katharin Theuser

All articles of this category (opens in new window) Die Welt der klinischen Studien wird immer komplexer. Umfangreiche regulatorische Änderungen in der EU und in Deutschland haben die Arbeitsweise im Rahmen klinischer Studien beeinflusst. Wer die Grundsätze der Good clinical Practice (GCP) …

Validation of the Questionnaire for the Structured Assessment of the Use of Complementary Medicine Methods and Procedures in Patients from the S3 Guideline Complementary Medicine in Oncology and Practical Use of it in Patients with Gynecological Cancer

Katharina Seitz, Anna‐Katharin Theuser, Carolin C. Hack, Peter A. Fasching et autres

Background: For the first time, an S3 guideline on complementary medicine in oncology was published in 2021, 2024 in May version 2.0 was published. The broad spectrum of complementary and integrative medicine was presented at the highest level of evidence, the respective …

de (code pays fourni par la source)

Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2 ‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial

Milena Beierlein, Lothar Häberle, Naiba Nabieva, Nicolaì Maass et autres

Patients with hormone receptor-positive (HRpos), HER2-negative (HER2neg) breast cancer (BC) benefit less from neoadjuvant chemotherapy (NACT) than patients with triple-negative and HER2-positive BC. In this retrospective analysis of the phase IV PreFace clinical trial (NCT01908556), where postmenopausal HRpos BC patients (n = …

de, us, ee, ch (code pays fourni par la source)

The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study

Andreas Schneeweiß, Peter A. Fasching, Marc Thill, Marion van Mackelenbergh et autres

BACKGROUND: Chemotherapies are still widely used in advanced breast cancer, specifically in patients with HER2-negative disease. This non-interventional real-world study assessed the utilization of nab-paclitaxel in a broad patient population with advanced breast cancer. METHODS: SERAPHINA (NCT02642406) was a single arm, non-interventional …

de (code pays fourni par la source)

Impact of risk and lifestyle factors on therapy goals in the treatment of breast cancer and gynecological cancer patients with integrative medicine

Katharina Seitz, Anna‐Katharin Theuser, Sophia Antoniadis, Matthias W. Beckmann et autres

BACKGROUND: As a result of advancements in the diagnosis and therapy of cancer, the prognosis for cancer patients has significantly improved. The benefits of a significantly enhanced survival time lead to a more extensive concern with quality of life and managing the …

de (code pays fourni par la source)

Effect of delayed isolation of peripheral blood mononuclear cells on cell viability and functionality

Sarah Lehle, Simon Völkl, Katharina Seitz, Chloë Goossens et autres

BACKGROUND: Peripheral blood mononuclear cells (PBMCs) are valuable biomarkers, providing crucial insights into the patients' immune system. Reliable biobanking of PBMCs is essential to minimize heterogeneity. In multicenter trials, blood sample transportation to central laboratories can increase the time between blood collection …

de (code pays fourni par la source)

Use of phytotherapy in patients with breast cancer

Anna‐Katharin Theuser, Carolin C. Hack, Matthias W. Beckmann, Peter A. Fasching et autres

Background: Herbal medicine is an integral part of Western traditional medicine. The use of herbal products is frequent. The aim of this study was to record the application behavior of patients with breast carcinoma compared to a healthy control group. Methods and …

de (code pays fourni par la source)

Use of complementary medicine methods and procedures in patients with malignant and benign breast lesions assessed by the questionnaire from the S3 guideline Complementary Medicine in Oncology

Lotte Brückner, CC Hack, MW Beckmann, Kwok‐Hung Au et autres

Background: The integration of complementary and integrative medicine (CIM) into breast cancer treatment is becoming increasingly important. The fact that CIM may interfere with cancer therapy leads to a great need for professional counselling of patients. It is necessary to take a …

de (code pays fourni par la source)

Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole

Peter A. Fasching, Carolin C. Hack, Naiba Nabieva, Nicolaì Maass et autres

BACKGROUND: The monarchE and NATALEE trials demonstrated the benefit of CDK4/6 inhibitor (CDK4/6i) therapy in adjuvant breast cancer (BC) treatment. Patient selection, based on clinical characteristics, delineated those at high (monarchE) and high/intermediate recurrence risk (NATALEE). This study employed a historical patient …

de, ch (code pays fourni par la source)

Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study

Alexander Hein, Peter A. Fasching, Carolin C. Hack, Nicolaì Maass et autres

Abstract Adjuvant treatment of patients with early-stage breast cancer (BC) should include an aromatase inhibitor (AI). Especially patients with a high recurrence risk might benefit from an upfront therapy with an AI for a minimum of five years. Nevertheless, not much is …

de, ch (code pays fourni par la source)

Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer

Paul Gaß, Falk C. Thiel, Lothar Häberle, Sven Ackermann et autres

Background Before the era of immunotherapies and antibody–drug conjugates, there were limited chemotherapeutic options for patients with recurrent and metastatic cervical cancer. Combination therapies with cisplatin have shown some superiority over monotherapy. This study examined platinum-free treatment regimens, comparing a combination of …

de, at (code pays fourni par la source)